Table 2.
Survival analysis via Cox regression
| Characteristic | HR (95% CI)‡ | P ‡ |
|---|---|---|
| Age | 1.03 (1.01–1.06) | 0.009 |
| Gender | ||
| Female (reference) | ||
| Male | 1.12 (0.65–1.94) | 0.68 |
| Residency region | ||
| Non‐north (reference) | ||
| North | 0.73 (0.46–1.16) | 0.18 |
| Comorbidity | ||
| Without (reference) | ||
| With† | 1.01 (0.64–1.60) | 0.96 |
| Smoking history | ||
| Without (reference) | ||
| With | 0.73 (0.39–1.37) | 0.33 |
| Treatment | ||
| CCRT (reference) | ||
| TKI | 0.71 (0.34–1.47) | 0.36 |
| Subtypes of stage IIIb | ||
| T3–4N3 (reference) | ||
| Others | 0.51 (0.33–0.80) | 0.003 |
| Use of PET | ||
| Without (reference) | ||
| With | 0.73 (0.48–1.11) | 0.14 |
†
Modified Carlson comorbidity score ≥ 1.
‡
Rounded.
CCRT, concurrent chemoradiotherapy; CI, confidence interval; HR, hazard ratio; PET, positron emission tomography; TKI, tyrosine kinase inhibitor.